Former CDC Director Julie Gerberding’s Stock at Merck
Julie Gerberding served as CDC Director from 2002-2009.
Dec 21, 2009 – Gerberding lands a job at Merck as president of vaccine division
June 24th, 2011 – Xonomy reports:
Julie Gerberding, the former director of the U.S. Centers for Disease Control and Prevention, has been in one of those rare positions for about the past 18 months as president of Merck’s vaccine unit. At Merck (NYSE: MRK), she has been learning the ins and outs of a $5-billion-a-year operation that makes 14 of the 17 vaccines the CDC recommends for children, and nine of the 10 recommended for adults. It would be an understatement to say this job carries a huge social responsibility, both to insure steady supplies of vaccines already on the market, and to develop new ones.
May 8, 2015 – Gerberding sells $2.3 million in stock
Dakota Financial News reported (archive.org):
Merck & Co. (NYSE:MRK) EVP Julie L. Gerberding sold 38,368 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $60.99, for a total transaction of $2,340,064.32. Following the completion of the transaction, the executive vice president now directly owns 31,985 shares of the company’s stock, valued at approximately $1,950,765.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Nov 7, 2016 – Gerberding sells $5.6 million in stock
Community Financial News reported (archive.org):
Merck & Co. (NYSE:MRK) EVP Julie L. Gerberding sold 85,523 shares of the business’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of €60.02 ($65.96), for a total value of €5,133,090.46 ($5,640,758.75). Following the completion of the transaction, the executive vice president now owns 77,762 shares in the company, valued at approximately €4,667,275.24 ($5,128,873.89). The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Between 2017 and Nov 2018, Gerberding has been buying and selling with over 43,000 shares.
|Trading Date||Type||Shares Traded||Price||Shares Held|
|6 Nov 2018||Buy||36,218||$54.68||46,263|
|6 Nov 2018||Sell||36,218||$75.14||46,263|
|14 May 2018||Sell||9,972||$59.66||45,717|
|26 Feb 2018||Buy||9,062||$54.72||55,277|
|1 May 2017||Sell||1,078||$62.38||45,338|
|1 May 2017||Buy||3,092||$0.00||45,338|
|26 Feb 2017||Buy||3,707||$65.85||43,063|
As of Dec 29, 2018 – Per Reuters – Gerberding holds 46,263 shares of stock at Merck & Co Inc (MRK), valued at $75.37 per share (or approx. value of $3,486,842.31). https://www.reuters.com/finance/stocks/insider-trading/MRK?symbol=&name=Gerberding+(Julie+L) – Archive.org
Former Conflict of Interest CDC Director Julie Gerberding Cashed Out on $5,640,758 in Shares of Merck Stock (NYSE:MRK) One Day Before the 2016 Presidential Election of @RealDonaldTrump. #COI #MERCK #Fascism
— 2ndfor1st (@2ndfor1st) January 31, 2018